[SCHEDULE 13D (Rule 13d-101) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) James M. Gregory SJ Strategic Investments, LLC 340 Martin Luther King, Jr. Boulevard, Suite 200 Bristol, TN 37620 (423) 989-8133 (Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications) March 20, 2014 (Date of Event which]
[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []
[SCHEDULE 13D (Rule 13d-101) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) James M. Gregory SJ Strategic Investments, LLC 340 Martin Luther King, Jr. Boulevard, Suite 200 Bristol, TN 37620 (423) 989-8133 (Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications) March 20, 2014 (Date of Event which]
[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []
[Title of each class Name of exchange on which registered American depositary shares, two of which represent one ordinary share, par value US$0.0005 per share Ordinary shares, par value US$0.0005 per share* * None (Title of Class) None (Title of Class) Indicate the number of outstanding shares of each of the Issuers classes of capital or common stock as of] [LOAN AGREEMENT between Wang Jingbo Yin Zhe Zhang Xinjun Wei Yan He Boquan Yan Qianghua and Shanghai Noah Rongyao Investment Consulting Co., Ltd. December 26, 2013 Loan Agreement This Loan Agreement (hereinafter referred to as this Agreement) is made on December, 26, 2013 in Shanghai by and between: 1. Wang Jingbo, a PRC citizen; 2. Yin Zhe, a PRC citizen;] [List of Significant Consolidated Entities of Noah Holdings Limited* Name Jurisdiction of Relationship with us Shanghai Noah Rongyao Investment Consulting Co., Ltd. China Wholly-owned subsidiary (1) Shanghai Noah Financial Services Co., Ltd. China Wholly-owned subsidiary (2) Noah Insurance (Hong Kong) Limited Hong Kong Wholly-owned subsidiary Kunshan Noah Xingguan Investment Management Co., Ltd. China Wholly-owned subsidiary Noah Holdings (Hong Kong) Limited] [I, Jingbo Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Noah Holdings Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,] [Certification by the Principal Financial Officer I, Theresa Teng, certify that: 1. I have reviewed this annual report on Form 20-F of Noah Holdings Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jingbo Wang Chief Executive Officer EX-13.1 6 d679366dex131.htm EX-13.1] [Certification by the Principal Financial Officer 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Theresa Teng Chief Financial Officer EX-13.2 7 d679366dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-171541 on Form S-8 of our reports dated March 24, 2014, relating to the consolidated financial statements and financial statement schedule of Noah Holdings Limited, and the effectiveness of Noah Holdings Limiteds internal control over financial reporting, appearing in this Annual Report] [[Letterhead of Zhong Lun Law Firm] March 24, 2014 Noah Holdings Limited No. 32 Qinhuangdao Road, Building C Shanghai 200082 Peoples Republic of China Dear Sirs, Yours faithfully, Zhong Lun Law Firm EX-15.2 9 d679366dex152.htm EX-15.2]
[Title of each class Name of exchange on which registered American depositary shares, two of which represent one ordinary share, par value US$0.0005 per share Ordinary shares, par value US$0.0005 per share* * None (Title of Class) None (Title of Class) Indicate the number of outstanding shares of each of the Issuers classes of capital or common stock as of] [LOAN AGREEMENT between Wang Jingbo Yin Zhe Zhang Xinjun Wei Yan He Boquan Yan Qianghua and Shanghai Noah Rongyao Investment Consulting Co., Ltd. December 26, 2013 Loan Agreement This Loan Agreement (hereinafter referred to as this Agreement) is made on December, 26, 2013 in Shanghai by and between: 1. Wang Jingbo, a PRC citizen; 2. Yin Zhe, a PRC citizen;] [List of Significant Consolidated Entities of Noah Holdings Limited* Name Jurisdiction of Relationship with us Shanghai Noah Rongyao Investment Consulting Co., Ltd. China Wholly-owned subsidiary (1) Shanghai Noah Financial Services Co., Ltd. China Wholly-owned subsidiary (2) Noah Insurance (Hong Kong) Limited Hong Kong Wholly-owned subsidiary Kunshan Noah Xingguan Investment Management Co., Ltd. China Wholly-owned subsidiary Noah Holdings (Hong Kong) Limited] [I, Jingbo Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Noah Holdings Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,] [Certification by the Principal Financial Officer I, Theresa Teng, certify that: 1. I have reviewed this annual report on Form 20-F of Noah Holdings Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jingbo Wang Chief Executive Officer EX-13.1 6 d679366dex131.htm EX-13.1] [Certification by the Principal Financial Officer 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Theresa Teng Chief Financial Officer EX-13.2 7 d679366dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-171541 on Form S-8 of our reports dated March 24, 2014, relating to the consolidated financial statements and financial statement schedule of Noah Holdings Limited, and the effectiveness of Noah Holdings Limiteds internal control over financial reporting, appearing in this Annual Report] [[Letterhead of Zhong Lun Law Firm] March 24, 2014 Noah Holdings Limited No. 32 Qinhuangdao Road, Building C Shanghai 200082 Peoples Republic of China Dear Sirs, Yours faithfully, Zhong Lun Law Firm EX-15.2 9 d679366dex152.htm EX-15.2]
